Long/short equity, biotech, small-cap

An Early Valuation Of Neuralstem's NSI-189 For MDD

Neuralstem (NYSEMKT:CUR) could be on the brink of something quite remarkable with their neurogenerative drug NSI-189. My last article covered what I thought to be an early valuation of what NSI-566, Neuralstem's ALS intraspinal stem cell therapy could be worth. In this article, I will attempt to do the same with NSI-189 for MDD.

MDD (Major Depressive Disorder)

MDD is characterized by a combination of symptoms that interfere with a person's ability to work, sleep, study, eat, and enjoy once-pleasurable activities. It is disabling and prevents a person from functioning normally. An episode of major depressive disorder may occur only once in a person's lifetime, but more often it occurs chronically throughout a person's life. Major depressive disorder...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details